[go: up one dir, main page]

DE60331925D1 - Krebstherapie mit ganzen glukan-teilchen und antikörpern - Google Patents

Krebstherapie mit ganzen glukan-teilchen und antikörpern

Info

Publication number
DE60331925D1
DE60331925D1 DE60331925T DE60331925T DE60331925D1 DE 60331925 D1 DE60331925 D1 DE 60331925D1 DE 60331925 T DE60331925 T DE 60331925T DE 60331925 T DE60331925 T DE 60331925T DE 60331925 D1 DE60331925 D1 DE 60331925D1
Authority
DE
Germany
Prior art keywords
glucan particles
whole glucan
antibodies
cancer therapy
immune system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60331925T
Other languages
English (en)
Inventor
Gary R Ostroff
Gordon D Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Louisville Research Foundation ULRF
Biopolymer Engineering Inc
Original Assignee
University of Louisville Research Foundation ULRF
Biopolymer Engineering Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60331925(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Louisville Research Foundation ULRF, Biopolymer Engineering Inc filed Critical University of Louisville Research Foundation ULRF
Application granted granted Critical
Publication of DE60331925D1 publication Critical patent/DE60331925D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
DE60331925T 2002-09-04 2003-09-04 Krebstherapie mit ganzen glukan-teilchen und antikörpern Expired - Lifetime DE60331925D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40812602P 2002-09-04 2002-09-04
PCT/US2003/027841 WO2004021994A2 (en) 2002-09-04 2003-09-04 Cancer therapy using whole glucan particles and antibodies

Publications (1)

Publication Number Publication Date
DE60331925D1 true DE60331925D1 (de) 2010-05-12

Family

ID=31978563

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60331925T Expired - Lifetime DE60331925D1 (de) 2002-09-04 2003-09-04 Krebstherapie mit ganzen glukan-teilchen und antikörpern

Country Status (9)

Country Link
US (3) US8883760B2 (de)
EP (3) EP1536820B2 (de)
JP (1) JP2006502167A (de)
CN (3) CN100363054C (de)
AT (1) ATE462437T1 (de)
AU (2) AU2003295326A1 (de)
CA (2) CA2496508C (de)
DE (1) DE60331925D1 (de)
WO (2) WO2004030613A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
AU2003258181A1 (en) 2002-08-13 2004-02-25 University Of Louisville Research Foundation Inc. Methods of using beta glucan as a radioprotective agent
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
CA2496508C (en) * 2002-09-04 2014-04-22 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
WO2005097204A1 (ja) 2004-04-09 2005-10-20 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
ES2375995T3 (es) * 2004-09-17 2012-03-08 University Of Massachusetts Composiciones y sus usos para deficiencias de enzima lisosomal.
US20070059310A1 (en) * 2005-05-03 2007-03-15 Karel Steven J Therapeutic combination compositions and methods of using same
WO2007084661A2 (en) * 2006-01-17 2007-07-26 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
MX2008016039A (es) 2006-06-15 2009-07-10 Biopolymer Engineering Inc Dba Preparacion de glucano.
EP2062588A4 (de) * 2006-08-24 2011-06-08 Kirin Holdings Kk Zusammensetzung zur linderung eines hautzustands
US20080167268A1 (en) * 2006-09-01 2008-07-10 Jun Yan Particulate beta-glucan compositions for regulating dendritic cells
WO2008027581A1 (en) * 2006-09-01 2008-03-06 University Of Louisville Mcrp antagonists and their uses
ES2397186T3 (es) * 2006-11-06 2013-03-05 Whitehead Institute Composiciones inmunomoduladoras y métodos para su uso
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
EP2222283A2 (de) 2007-10-29 2010-09-01 University of Massachusetts Zur freisetzung von nukleinsäuren (sirna) mit hefe-zellwandproteinen verkapselte mehrlagige nanopatikel
US20120003178A1 (en) * 2008-02-19 2012-01-05 Novogen Research Pty Ltd Evaluating the therapeutic potential of a glucan
WO2009103116A1 (en) * 2008-02-19 2009-08-27 Novogen Research Pty Ltd Ex vivo cell stimulation
US20130064855A1 (en) * 2011-09-12 2013-03-14 Baylor Research Institute Reprogramming immune environment in breast cancer via dendritic cells
ES2661393T3 (es) * 2012-04-30 2018-03-28 Biothera, Inc. Preparación inmunoterapéutica de beta glucano
MX362256B (es) 2012-05-07 2019-01-09 Algal Scient Corporation Proceso de multiples etapas para produccion de un modulador inmune.
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
US9738731B2 (en) * 2013-03-08 2017-08-22 Tokyo University Of Science Foundation Lactic acid bacterium growth enhancer, regulatory T-cell number increasing agent, method of enhancing growth of lactic acid bacterium, method of increasing number of regulatory T-cells, method of evaluating regulatory T-cell number increasing effect, and method of evaluating lactic acid growth enhancing effect
EP2832360A1 (de) 2013-07-30 2015-02-04 Fresenius Kabi Deutschland GmbH Polysaccharid zur Verwendung bei der Prävention der Bildung von Metastasen und/oder Rezidiven
CA2932192C (en) * 2013-12-05 2020-10-06 Biothera, Inc. .beta.-glucan assay methods
CN106456532B (zh) * 2014-03-05 2020-07-24 奥比思健康解决方案有限责任公司 使用酵母细胞壁颗粒的疫苗递送系统
LT6145B (lt) 2014-04-14 2015-04-27 Uab "Biocentras" TERAPINĖ ß-GLIUKANŲ KOMPOZICIJA, MODULIUOJANTI ŽMOGAUS IMUNINĘ SISTEMĄ IR INICIJUOJANTI VĖŽINIŲ LĄSTELIŲ ARDYMĄ
ES2877099T3 (es) * 2014-07-10 2021-11-16 Hibercell Inc Beta-glucano en combinación con agentes anticáncer que afectan al microambiente tumoral
JP6887378B2 (ja) 2014-11-06 2021-06-16 バイオセラ，インク． 腫瘍内微小環境に影響を与えるベータ−グルカン方法と組成物
US20180110853A1 (en) * 2016-10-21 2018-04-26 Wisconsin Alumni Research Foundation Vaccine Adjuvant
JP2019536811A (ja) * 2016-12-07 2019-12-19 イネイト バイオセラピューティクス， エルエルシー β−１，６−グルカンのトラスツズマブ抗体コンジュゲート
JP7254350B2 (ja) 2016-12-07 2023-04-10 イネイト バイオセラピューティクス， エルエルシー β－１，６－グルカン治療用抗体コンジュゲート
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
CA3059259C (en) 2017-04-10 2022-07-05 Kibow Biotech, Inc. Multifiber prebiotic composition for digestive health, weight control, boosting immunity and improving health
EA202092158A1 (ru) * 2018-03-13 2020-12-25 Хиберселл, Инк. Комбинированная иммунотерапия бета-глюканом и агонистом cd40
JP7088502B2 (ja) * 2019-09-11 2022-06-21 株式会社アウレオ 抗体医薬の効果増強用組成物
EP3858362A1 (de) 2020-01-29 2021-08-04 Pleuran, s.r.o. Beta-glucan zur verwendung bei der verbesserung der anti-tumor-immunität bei remission
WO2021152497A1 (en) * 2020-01-29 2021-08-05 Pleuran, S.R.O. Beta-glucan for use in modulation of an immune response in a remission
WO2022251123A1 (en) * 2021-05-24 2022-12-01 Frank Jordan Alkaline extraction of beta glucan compounds for use in anti-viral and immune therapies

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943247A (en) * 1972-05-22 1976-03-09 Kaken Kagaku Kabushiki Kaisha Treatment of bacterial infections with glucan compositions
US3903297A (en) * 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US4138479A (en) * 1975-11-07 1979-02-06 Bayer Aktiengesellschaft Process for the preparation of immunopotentiating agents from components of yeast cell wall material
JPS5461112A (en) * 1977-10-24 1979-05-17 Ono Pharmaceut Co Ltd Oncostatic polysaccharide* its preparation* and oncostatic drugs containing it as an effective component
JPS58220989A (ja) * 1982-06-14 1983-12-22 Diesel Kiki Co Ltd 可変容量式ベ−ン型圧縮機
SE456911B (sv) * 1983-12-19 1988-11-14 Olle Larm Vattenloeslig, aminerad beta-1,3-bunden d-glukan och makrofagstimulerande komposition innehaallande densamma
US5037972A (en) 1984-11-28 1991-08-06 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4992540A (en) * 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5250436A (en) 1984-11-28 1993-10-05 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5082936A (en) 1984-11-28 1992-01-21 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5028703A (en) * 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
CA1340080C (en) * 1985-03-11 1998-10-13 Dorothee Herlyn Human tumor therapy
US4975421A (en) * 1985-08-19 1990-12-04 Bioglucan, Lp. Soluble phosphorylated glucan: methods and compositions for wound healing
US4900722A (en) * 1985-08-19 1990-02-13 Bioglucans, L.P. Methods and compositions for prophylactic and therapeutic treatment of infections
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US5221616A (en) * 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
KR0141685B1 (ko) * 1988-09-01 1998-07-01 야마따니 와따루 참게 아메보사이트 라이세이트 g 인자 활성화 저해제
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE151110T1 (de) 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5057503A (en) * 1989-01-23 1991-10-15 The Brigham And Women's Hospital Derivativized polysaccharides with biologic activity, method of their isolation, and uses therefor
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US4946450A (en) * 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
IT1232310B (it) 1989-09-04 1992-01-28 Consiglio Nazionale Ricerche Processo per la preparazione di un prodotto contenente glucano a partire da candida albicans bmm-12
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
ES2103276T3 (es) * 1989-09-08 1997-09-16 Alpha Beta Technology Composicion para la activacion del sistema inmunitario.
EP0490995A1 (de) * 1989-09-08 1992-06-24 Alpha Beta Technology Verfahren zur herstellung von wasserlöslichen glukanen
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
US5223491A (en) * 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JP2911554B2 (ja) * 1990-06-25 1999-06-23 台糖株式会社 抗ウィルス剤
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3122454B2 (ja) * 1990-09-27 2001-01-09 生化学工業株式会社 カブトガニ・アメボサイト・ライセートの調製法
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
EP0580737B1 (de) 1991-04-10 2004-06-16 The Scripps Research Institute Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
IT1256035B (it) 1992-08-10 1995-11-21 Consiglio Nazionale Ricerche Glucani ad attivita' immunostimolante
US5453124A (en) * 1992-12-30 1995-09-26 Texas Instruments Incorporated Programmable multizone gas injector for single-wafer semiconductor processing equipment
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
GB9420645D0 (en) * 1994-10-13 1994-11-30 Dow Chemical Co Non-linear stytrenic polymer compositions and articles prepared therefrom
US5576015A (en) 1995-03-02 1996-11-19 Donzis; Byron A. Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
AUPN166195A0 (en) 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
US6036946A (en) * 1997-12-24 2000-03-14 Shaklee Corporation Methods for protecting skin from damaging effects of ultraviolet light
AU6033299A (en) * 1998-09-14 2000-04-03 Nabi Compositions of beta-glucans and specific igiv
US6369216B1 (en) * 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
WO2002058711A1 (en) * 2001-01-16 2002-08-01 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
AU2003258181A1 (en) * 2002-08-13 2004-02-25 University Of Louisville Research Foundation Inc. Methods of using beta glucan as a radioprotective agent
CA2496508C (en) 2002-09-04 2014-04-22 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
CN1964722A (zh) 2004-05-10 2007-05-16 生物聚合物工程有限公司 与抗生素、疫苗和病毒单克隆抗体组合的全葡聚糖颗粒

Also Published As

Publication number Publication date
CN1697659A (zh) 2005-11-16
CN1694715A (zh) 2005-11-09
JP2006502167A (ja) 2006-01-19
AU2003295326A1 (en) 2004-04-23
CA2496596A1 (en) 2004-03-18
US8883760B2 (en) 2014-11-11
EP1536820B2 (de) 2013-10-23
EP1539194A4 (de) 2007-06-13
ATE462437T1 (de) 2010-04-15
EP1539194A2 (de) 2005-06-15
US20060009419A1 (en) 2006-01-12
WO2004021994A3 (en) 2004-08-12
EP1536820A2 (de) 2005-06-08
US20150064199A1 (en) 2015-03-05
CA2496508C (en) 2014-04-22
CN1694715B (zh) 2010-12-01
EP1536820B1 (de) 2010-03-31
CA2496596C (en) 2016-06-28
EP2181711A1 (de) 2010-05-05
EP1536820A4 (de) 2007-06-20
AU2003268486A8 (en) 2004-03-29
WO2004030613A3 (en) 2005-01-13
AU2003268486A1 (en) 2004-03-29
WO2004030613A2 (en) 2004-04-15
CN100363054C (zh) 2008-01-23
AU2003295326A8 (en) 2004-04-23
US20170056432A1 (en) 2017-03-02
CN1939335A (zh) 2007-04-04
CA2496508A1 (en) 2004-04-15
US9522187B2 (en) 2016-12-20
WO2004021994A2 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
ATE462437T1 (de) Krebstherapie mit ganzen glukan-teilchen und antikörpern
WO2005081854A3 (en) Egf receptor epitope peptides and uses thereof
UA109108C2 (uk) Антитіло до pd-l1 та його застосування для посилення функції t-клітин
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
DE60333121D1 (de) Pers 14.18, der gd2 bindet und seine fusion mit il-2
HK1134098A1 (en) Antibodies binding to the tumour associated antigen tat10772 for the diagnosis and treatment of tumor
WO2008070042A3 (en) High potency recombinant antibodies, methods for producing them and use in cancer therapy
TNSN05300A1 (en) Treatment with anti-vegf antibodies
ATE519501T1 (de) Rekombinanter anti-cd40 antikörper und dessen anwendungen
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
WO2011070214A8 (es) Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
MX2021002605A (es) Anticuerpos anti-cxcl13 para el tratamiento de enfermedades autoinmunes y cancer.
DE602006019977D1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
EP3674321A3 (de) Anti-met-antikörper und verwendungen davon
BRPI0515604A (pt) método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
WO2007144046A3 (de) Mittel zur behandlung von malignen erkrankungen
MX2022004086A (es) Anticuerpos anti inmunorreceptor de celulas t con dominios de inmunoglobulina y motivo inhibidor basado en tirosina de inmunorreceptor (tigit) y sus usos.
WO2006085895A3 (en) Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
ATE536887T1 (de) Kovalente konjugate zwischen mit artemisinin verwandten endoperoxiden und eisentragenden proteinen und anwendungsverfahren
TR200902344T1 (tr) Anti-epidermal büyüme faktörü reseptör antikorları ile terapinin etkisinin geliştirilmesi için terapötik bileşimler.
MX2024006212A (es) Métodos para usar agonistas del rar? para tratamiento del cáncer.
PH12022550595A1 (en) Anti-tigit antibodies and uses thereof

Legal Events

Date Code Title Description
8363 Opposition against the patent